Latest News
14
2023
Sep
Greenyn Biotechnology Receives Recognition for Health Supplement Innovation Award
Taipei, Taiwan – Greenyn Biotechnology (6846), in collaboration with the National Research Institute, has spent over a decade in the development of patented plant extract materials, RabenLiv® and RabenWhite®. These outstanding innovations were recognized at the International Symposium on Food and Health for Long Covid on March 10th, where they were presented with the " Health Supplement Innovation Award". This accolade reaffirms the high quality of Greenyn Biotechnology's research outcomes.
According to Greenyn Biotechnology, RabenLiv® and RabenWhite® are patented raw materials derived from native plants- Crassocephalum rabens after the identification of their active ingredients (HCP774® and CRK774®). The company's research and development team conducted a series of cultivation technology improvements, including seedling optimization, field planning, fertilization planning, and planting mode changes, to ensure the stability of the active ingredients' production and output. Through scientific cultivation techniques, the content of key components produced is over 11 times higher than that of wild species, and stability has increased by more than twofold. This achievement realizes the vision of quantifying high-quality agricultural raw materials in Taiwan. The two novel health supplement raw materials derived from precision extraction technology also inject powerful vitality into the international health supplement market.
Dr. Pang-Kuei Hsu, Chief Research and Development Officer at Greenyn Biotechnology stated, "Although Taiwan is small in size, it is a treasure trove of abundant natural resources. Elevating these treasures to the international health supplement market has always been the goal of the Greenyn Biotechnology research and development team." Among these, HCP774® helps in adjusting body constitution, reducing internal heat, and maintaining health. Meanwhile, CRK774®, supported by clinical trials, is a rising star in the beauty and health market serving as a nutritional supplement for maintaining youthful beauty.
Greenyn Biotechnology has over 70 worldwide patents and published in international journals to suit market need for precision clinical studies and efficacy certifications. It is also the first domestic biotechnology company to receive FDA approval for Taiwan's national treasure, Antromax® antrodia cinnammomea mycelia, and bitter melon extract (including mcIRBP-19) Insumate® as new dietary ingredients (NDIs). The group's structure and growth possibilities have also been noted by investors. It became an OTC-listed business in the prior quarter after passing the OTC review.
News URL
1.yahoo!新聞
